Study identifier:D7260C00004
ClinicalTrials.gov identifier:NCT06555822
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I Randomized, Single-blind, Placebo-controlled Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD5004 in Healthy Participants
Healthy Participants
Phase 1
Yes
AZD5004, Placebo
All
15
Interventional
18 Years - 55 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Oct 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: AZD5004 Participants will receive AZD5004 orally. | Drug: AZD5004 AZD5004 will be administered as an oral tablet once daily. Other Name: ECC5004 |
Placebo Comparator: Placebo Participants will receive matching Placebo orally. | Drug: Placebo Placebo will be administered as an oral tablet once daily. |